Sociedad Americana de Hirudoterapia

Ministry of Health of Trinidad and Tobago — Chemistry, Food and Drugs Division (Drug Inspectorate)

T&T Drug Inspectorate · Trinidad and Tobago · latin america

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Trinidad and Tobago's Drug Inspectorate (Chemistry, Food and Drugs Division, Ministry of Health) — leech-specific regulatory pathway has not been independently verified by ASH; medicinal leeches fall under the general national medical device framework as appropriate.

Regulatory Profile

Agency type
national regulator
Region
latin america
Country
Trinidad and Tobago
Leech status
unregulated
Last ASH review
2026-05-26

Relevant Regulation Codes

  • Trinidad and Tobago Food and Drugs Act, Chapter 30:01
  • Trinidad and Tobago national medical device regulatory framework

Prescriber Requirements

  • Medical Board of Trinidad and Tobago–registered physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

Ministry of Health registration as applicable; English-language labelling. Standard cold-chain conditions.

Import/Export Rules

Ministry of Health import authorisation; Animal Production and Health Division clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

Not covered under public insurance schemes for leech therapy specifically.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general medical device / traditional medicine framework as appropriate. CARPHA (Caribbean Public Health Agency) and CARICOM harmonisation may affect device approvals; the exact mechanism has not been independently mapped by ASH. Region assigned as latin-america for coverage purposes pending Caribbean sub-region implementation.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.